Acute kidney injury in patients with COVID-19: severity of inflammatory response and risk of chronic kidney disease development
- Authors: Mikhailova L.V.1, Perepelitsa S.A.1, Struchkov S.T.1, Orlova Y.A.1, Akchurina K.N.1
-
Affiliations:
- Immanuel Kant Baltic Federal University
- Issue: Vol 17, No 1 (2025)
- Pages: 29-32
- Section: Original Articles
- URL: https://journal-vniispk.ru/2075-3594/article/view/293197
- DOI: https://doi.org/10.18565/nephrology.2025.1.29-32
- ID: 293197
Cite item
Open Access
Access granted
Subscription Access
Abstract
Objective. Evaluation of the functional state of the kidneys in patients with acute kidney injury (AKI) after COVID-19, one year or more after hospitalization.
Material and methods: The analysis of data from 437 patients who had COVID-19 and were discharged from the hospital in 2021 and 2022 was performed. The creatinine, blood urea, CRP, ferritin, lactate dehydrogenase, interleukin-6 levels during hospitalization and the dynamics of creatinine, blood urea, estimated glomerular filtration rate a year or more after hospitalization and the presence of concomitant somatic diseases were assessed.
Results. At the time of hospitalization, 76 (20.5%) patients had signs of AKI. Patients with AKI were statistically significantly older, they were more likely to have arterial hypertension, coronary artery disease and diabetes mellitus, and they had higher levels of inflammatory markers during hospitalization. One year or more after hospitalization, creatinine and urea levels, as well as the number of patients with stage 3 chronic kidney disease, were higher among patients who had COVID-19 with AKI.
Full Text
##article.viewOnOriginalSite##About the authors
Larisa V. Mikhailova
Immanuel Kant Baltic Federal University
Author for correspondence.
Email: mihalysa@mail.ru
ORCID iD: 0000-0001-5070-5955
Cand.Sci. (Med.), Associate Professor, Head of the Therapy Department, Institute of Medicine and Life Sciences (MEDBIO)
Russian Federation, KaliningradSvetlana A. Perepelitsa
Immanuel Kant Baltic Federal University
Email: sveta_perepeliza@mail.ru
ORCID iD: 0000-0002-4535-9805
Dr.Sci. (Med.), Head of the Department of Surgical Disciplines, Institute of Medicine and Life Sciences (MEDBIO), Leading Researcher, Negovsky Research Institute of General Reanimatology, Federal Scientific and Clinical Center for Intebsive Care Medicine and Rehabilitology
Russian Federation, KaliningradSergey T. Struchkov
Immanuel Kant Baltic Federal University
Email: sergey17011990@gmail.com
ORCID iD: 0009-0004-7886-3655
2nd year clinical resident physician, specialty “therapy”, Institute of Medicine and Life Sciences (MEDBIO)
Russian Federation, KaliningradYulia A. Orlova
Immanuel Kant Baltic Federal University
Email: yuliya_orlova2001@mail.ru
6th year student, specialty 31.05.01 “General Medicine”, Institute of Medicine and Life Sciences (MEDBIO)
Russian Federation, KaliningradKsenia N. Akchurina
Immanuel Kant Baltic Federal University
Email: ksyu.akchurina.01@mail.ru
ORCID iD: 0009-0000-4996-380X
6th year student, specialty 31.05.01 “General Medicine”, Institute of Medicine and Life Sciences (MEDBIO)
Russian Federation, KaliningradReferences
- Wang L., Li X., Chen H., et al. Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. Am. J. Nephrol. 2020;51(5):343–8. doi: 10.1159/000507471.
- Hirsch J.S., Ng J.H., Ross D.W., et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209–18. doi: 10.1016/j.kint.2020.05.006.
- Richardson S., Hirsch J.S., Narasimhan M., et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area [published correction appears in JAMA. 2020 May 26;323(20):2098. doi: 10.1001/jama.2020.7681]. JAMA. 2020;323(20):2052–9. doi: 10.1001/jama.2020.6775.
- Fu E.L., Janse R.J., de Jong Y., et al. Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis. Clin Kidney J. 2020;13(4):550–63. Published 2020 Sep 2. doi: 10.1093/ckj/sfaa160.
- Sharma P., Ng J.H., Bijol V., et al. Pathology of COVID-19-associated acute kidney injury. Clin. Kidney J. 2021;14(Suppl. 1):i30–9. Published 2021 Jan 24. doi: 10.1093/ckj/sfab003.
- Stewart B.J., Ferdinand J.R., Young M.D., et al. Spatiotemporal immune zonation of the human kidney. Science. 2019;365(6460):1461–6. doi: 10.1126/science.aat5031.
- Limbutara K., Chou C.L., Knepper M.A. Quantitative Proteomics of All 14 Renal Tubule Segments in Rat. J. Am. Soc. Nephrol. 2020;31(6):1255–66. doi: 10.1681/ASN.2020010071.
- Kissling S., Rotman S., Gerber C., et al. Collapsing glomerulopathy in a COVID-19 patient. Kidney Int. 2020;98(1):228–31. doi: 10.1016/j.kint.2020.04.006.
- Li X., Geng M., Peng Y., et al. Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal. 2020;10(2):102–8. doi: 10.1016/j.jpha.2020.03.001.
- Su H., Yang M., Wan C., et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219–27. doi: 10.1016/j.kint.2020.04.003.
- Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter. Suppl. 2012;1:1–126.
- Diao B., Wang C., Wang R., et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat. Commun. 2021;12(1):2506. Published 2021 May 4. doi: 10.1038/s41467-021-22781-1.
- Sette А., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–80. Published online 2021 Jan 12. doi: 10.1016/j.cell.2021.01.007. [PMID: 33497610, PMCID: PMC7803150].
- Song P., Li W., Xie J., et al. Cytokine storm induced by SARS-CoV-2. Clin. Chim. Acta. 2020;509:280–7. doi: 10.1016/j.cca.2020.06.017. [Epub 2020 Jun 10, PMID: 32531256, PMCID: PMC7283076].
- Khomich O.A., Kochetkov S.N., Bartosch B., Ivanov A.V. Redox Biology of Respiratory Viral Infections. Viruses. 2018;10(8):392. Published 2018 Jul 26. doi: 10.3390/v10080392.
- Monteil V., Kwon H., Prado P., et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020;181(4):905–13.e7. doi: 10.1016/j.cell.2020.04.004.
- Hamming I., Timens W., Bulthuis M.L., et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203(2):631–7. doi: 10.1002/path.1570.
- Varga Z., Flammer A.J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8. doi: 10.1016/S0140-6736(20)30937-5.
Supplementary files
